These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29382383)

  • 1. Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab.
    Cafuir L; Lawson D; Desai N; Kesner V; Voloschin A
    J Immunother Cancer; 2018 Jan; 6(1):11. PubMed ID: 29382383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
    Garcia CA; El-Ali A; Rath TJ; Contis LC; Gorantla V; Drappatz J; Davar D
    J Immunother Cancer; 2018 Aug; 6(1):83. PubMed ID: 30170622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients.
    Patel AS; Snook RJ; Sehdev A
    Discov Med; 2019 Aug; 28(152):107-111. PubMed ID: 31926582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute demyelinating polyneuropathy induced by nivolumab.
    Fukumoto Y; Kuwahara M; Kawai S; Nakahama K; Kusunoki S
    J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):435-437. PubMed ID: 28844069
    [No Abstract]   [Full Text] [Related]  

  • 5. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma.
    Manousakis G; Koch J; Sommerville RB; El-Dokla A; Harms MB; Al-Lozi MT; Schmidt RE; Pestronk A
    Muscle Nerve; 2013 Sep; 48(3):440-4. PubMed ID: 23447136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus-induced polyneuropathy after heart transplantation.
    Labate A; Morelli M; Palamara G; Pirritano D; Quattrone A
    Clin Neuropharmacol; 2010 May; 33(3):161-2. PubMed ID: 20502136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma.
    Samara Y; Yu CL; Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):966-968. PubMed ID: 29444608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
    Liao B; Shroff S; Kamiya-Matsuoka C; Tummala S
    Neuro Oncol; 2014 Apr; 16(4):589-93. PubMed ID: 24482447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute visual loss after ipilimumab treatment for metastatic melanoma.
    Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
    J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.
    Supakornnumporn S; Katirji B
    J Clin Neuromuscul Dis; 2017 Dec; 19(2):80-83. PubMed ID: 29189553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab.
    Ruff MW; Mauermann ML
    Neurologist; 2018 May; 23(3):98-99. PubMed ID: 29722744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    McDonald MA; Sanghvi P; Bykowski J; Daniels GA
    BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Digital ischaemia with fingertip ulcers during ipilimumab therapy].
    Zenati N; Charles J; Templier I; Blaise S
    Ann Dermatol Venereol; 2020 Mar; 147(3):212-216. PubMed ID: 31864764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.
    Choe JH; Andonian BJ; Kim GJ; Salama AK
    Immunotherapy; 2016 Oct; 8(10):1163-7. PubMed ID: 27605066
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic inflammatory demyelinating polyneuropathy mimicking a lumbar spinal stenosis syndrome.
    Ginsberg L; Platts AD; Thomas PK
    J Neurol Neurosurg Psychiatry; 1995 Aug; 59(2):189-91. PubMed ID: 7629539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon α-2b: a neuropathology case report.
    Shiga K; Tanaka E; Isayama R; Mizuno T; Itoh K; Nakagawa M
    Intern Med; 2012; 51(2):217-21. PubMed ID: 22246494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.